Clinical Study of 18F-LNC1007 Injection PET/CT

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

March 2, 2025

Study Completion Date

March 2, 2025

Conditions
Healthy VolunteersCancer Patients
Interventions
DRUG

18F-LNC1007 Injection

Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.

Trial Locations (1)

Unknown

Precision Molecular Imaging & Theranostics (trading as Melbourne Theranostic Innovation Centre), Melbourne

All Listed Sponsors
lead

Yantai LNC Biotechnology Singapore PTE. LTD.

INDUSTRY

NCT06471712 - Clinical Study of 18F-LNC1007 Injection PET/CT | Biotech Hunter | Biotech Hunter